Dan Shechtman starts presidential campaign


Dan Shechtman, who won the chemistry Nobel in 2011 for his work on quasicrystals, has begun his campaign to become president of Israel, meeting with politicians at the Knesset, the legislative arm of Israel’s government.

He needs the support of at least 10 Knesset members to run in the upcoming election, which is expected to take place in June this year. Shechtman announced his intention to run in January, telling Israel’s Channel 1 news programme that he wanted to improve the lives of Israel’s citizens. ‘I already am changing things in many areas, especially in the field of education, higher education and technological innovation. I think that as president I will be able to do much more,’ he said.

In Israel the president is a ceremonial figurehead without much political power. Nevertheless, most presidents tend to be former politicians. If Shechtman wins, he will be the first non-politician to be elected since biophysicist Ephraim Katzir in 1973.

His bid to run for president has already drawn public support in Israel. A petition on the Israeli site Atzuma supporting his nomination has collected over 15,000 signatures.


Related Content

Crystals that aren't quite crystalline win Nobel

5 October 2011 News Archive

news image

The 2011 Nobel Prize in Chemistry has been awarded to Dan Shechtman for his discovery of quasicrystals

Quasicrystals Scoop Prize

28 October 2011 Feature

news image

This year's Nobel laureate in chemistry fought hard to win acceptance of his discovery: quasicrystals. Laura Howes tells how ...

Most Read

Computational tool leaves electrides with nowhere to hide

25 February 2015 Research

news image

Electride criteria pave way for new research into these fascinating materials

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent